Cargando…

Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images

BACKGROUND: Epidermal growth factor receptor (EGFR) genotyping and programmed death ligand-1 (PD-L1) expressions are of paramount importance for treatment guidelines such as the use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in lung cancer. Conventional identificati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chengdi, Ma, Jiechao, Shao, Jun, Zhang, Shu, Liu, Zhongnan, Yu, Yizhou, Li, Weimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895233/ https://www.ncbi.nlm.nih.gov/pubmed/35250988 http://dx.doi.org/10.3389/fimmu.2022.813072

Ejemplares similares

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC
por: Wang, Chengdi, et al.
Publicado: (2022)

Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images
por: Shao, Jun, et al.
Publicado: (2022)

Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images
por: Wang, Chengdi, et al.
Publicado: (2021)

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
por: Li, Yujing, et al.
Publicado: (2023)

Immune regulation and emerging roles of noncoding RNAs in Mycobacterium tuberculosis infection
por: Liang, Shufan, et al.
Publicado: (2022)

The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID
por: Li, Jingwei, et al.
Publicado: (2023)

Development and validation of an abnormality-derived deep-learning diagnostic system for major respiratory diseases
por: Wang, Chengdi, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

DeepLN: A Multi-Task AI Tool to Predict the Imaging Characteristics, Malignancy and Pathological Subtypes in CT-Detected Pulmonary Nodules
por: Wang, Chengdi, et al.
Publicado: (2022)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy
por: Lin, Jing, et al.
Publicado: (2022)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
por: Zhou, Shujie, et al.
Publicado: (2022)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status
por: Shao, Jun, et al.
Publicado: (2021)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers
por: Lei, Youming, et al.
Publicado: (2022)

Predictive Power of a Radiomic Signature Based on (18)F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
por: Li, Xiaofeng, et al.
Publicado: (2019)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC
por: Lin, Liaoyi, et al.
Publicado: (2020)

PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features
por: Huang, Weicheng, et al.
Publicado: (2022)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

The Application of Artificial Intelligence in the Diagnosis and Drug Resistance Prediction of Pulmonary Tuberculosis
por: Liang, Shufan, et al.
Publicado: (2022)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
por: Tu, Eric, et al.
Publicado: (2022)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC
por: Hamakawa, Yusuke, et al.
Publicado: (2023)

AI-based analysis of CT images for rapid triage of COVID-19 patients
por: Xu, Qinmei, et al.
Publicado: (2021)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients—a radiomics nomogram analysis
por: Yang, Xiaoyan, et al.
Publicado: (2021)

End to End Multitask Joint Learning Model for Osteoporosis Classification in CT Images
por: Zhang, Kun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ceintfrqhhce5h6pnu6j4ckstu